Human Immunodeficiency Virus Clinical Trial
Official title:
Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population
Purpose: To see how growing older changes the amount of HIV drugs in the blood of
HIV-infected men and women. Many changes happen in the body as it ages that may affect the
way drugs are carried in the blood, broken down or removed from the body. This study will
look at the amount of drug in the blood and cells of the immune system for patients taking
efavirenz, tenofovir and emtricitabine or atazanavir boosted with ritonavir, tenofovir and
emtricitabine.
Participants: The population will comprise of 56 (6 for intensive PK and 50 for sparse
sampling) HIV-infected adults currently adhering to an antiretroviral regimen containing
efavirenz with tenofovir and emtricitabine and the same number and distribution of
HIV-infected adults currently adhering to an antiretroviral regimen containing atazanavir
boosted with ritonavir with tenofovir and emtricitabine.
Procedures (methods): This study will be completed at the University of North Carolina at
Chapel Hill. There will be four groups of subjects: Efavirenz/tenofovir/emtricitabine Group
A, Efavirenz/tenofovir/emtricitabine Group B, Atazanavir/ritonavir/tenofovir/emtricitabine
Group A, and Atazanavir/ritonavir/tenofovir/emtricitabine Group B.
The initial six subjects (Group A) for intensive PK analysis for each regimen will be
recruited from the the UNC ID Clinic or the Moses Cone Health System Infectious Diseases
Clinic, and will be comprised of non-frail subjects not currently receiving interacting
drugs. If subjects provide informed consent, timed blood samples will be obtained to
determine pharmacokinetic parameters around an observed dose of one of the two study
regimens. A whole blood sample will also be collected and stored for potential drug
metabolizing enzymes and transporters genotyping in the future. Group A subjects will
complete a follow-up visit after their sampling visit.
50 subsequent subjects (Group B) for each regimen will be screened simultaneously, with no
more than 10 subjects enrolled for each regimen in Group B prior to the completion and
analysis of Group A. These subjects will also be recruited from either site. Group B
subjects will have one or two sampling visits with 1 to 4 blood samples obtained at each
visit, with a stored sample for future genotyping obtained on one of the visits. Samples
will be collected just prior to a dose, at 2 hours, between 4 and 6 hrs, and between 10 and
14 hours after a medication dose. These visits may coincide with the subjects' regularly
scheduled visit to the clinic, or be scheduled separately, depending on the preference and
availability of the subject.
n/a
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03516318 -
Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria
|
N/A | |
| Completed |
NCT04653194 -
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
|
Phase 3 | |
| Completed |
NCT01792570 -
DRV/r + RPV QD: Efficacy and Toxicity Reduction
|
Phase 3 | |
| Active, not recruiting |
NCT04826562 -
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
|
Phase 4 | |
| Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
| Completed |
NCT02812329 -
Intervention to Encourage HIV Testing and Counseling Among Adolescents
|
Phase 1 | |
| Completed |
NCT02919306 -
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT02651376 -
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02516930 -
A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China
|
N/A | |
| Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
| Completed |
NCT01944371 -
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01778374 -
Mater-Bronx Rapid HIV Testing Project.
|
N/A | |
| Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
| Completed |
NCT01076179 -
Kaletra in Combination With Antiretroviral Agents
|
N/A | |
| Completed |
NCT01460433 -
Problems With Immune Recovery in the Gut Tissue
|
N/A | |
| Completed |
NCT01490346 -
Tissue Drug Levels of HIV Medications
|
N/A | |
| Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
| Terminated |
NCT04240210 -
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
|
Phase 4 | |
| Active, not recruiting |
NCT04704336 -
Integration of Hypertension Management Into HIV Care in Nigeria
|
N/A | |
| Completed |
NCT03254277 -
3BNC117-LS First-in-Human Phase 1 Study
|
Phase 1 |